Neuroblastomas are tumours of sympathetic origin, with a heterogeneous clinical course
ranging from localized or spontaneously regressing to widely metastatic disease …

Mammalian target of rapamycin (mTOR) is a highly conserved Serine/Threonine (Ser/Thr)
protein kinase, which belongs to phosphatidylinositol-3-kinase-related kinase (PIKK) protein …

Vα24-invariant natural killer T cells (NKTs) have anti-tumor properties that can be enhanced
by chimeric antigen receptors (CARs). Here we report updated interim results from the first-in …

Background Immune checkpoint inhibitors targeting PD-1 have shown clinical benefit in
adults with cancer, but data on these drugs in children are scarce. We did a phase 1–2 study …

Gangliosides are carbohydrate-containing sphingolipids that are widely expressed in
normal tissues, making most subtypes unsuitable as targets for cancer therapy. However …

Immunotherapy holds great promise for the treatment of pediatric cancers. In neuroblastoma,
the recent implementation of anti-GD2 antibody Dinutuximab into the standard of care has …

There is an urgent need to identify novel therapies for childhood cancers. Neuroblastoma is
the most common pediatric solid tumor, and accounts for~ 15% of childhood cancer‐related …

Neuroblastoma is a neural crest derived malignancy of the peripheral nervous system and is
the most common and deadliest tumor of infancy. It is characterized by clinical heterogeneity …

Neuroblastoma is the most common extra-cranial solid tumor of childhood and the most
common in the first year of life. It is a unique malignancy in that infants often present with …

While the adoption of multimodal therapy including surgery, radiation, and aggressive
combination chemotherapy has improved outcomes for many children with high-risk …